Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2022-07-09
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-14 (study day 21); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 65); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 132); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 156); relationship: N
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 159); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.